Antengene与UCB达成了一项600万美元的自免疫疗法平台协议,潜在支付超过11亿美元,并计划在2026年进行关键胃癌试验. Antengene secured a $60M deal with UCB for its autoimmune therapy platform, with potential payments over $1.1B and a pivotal gastric cancer trial planned for 2026.

Antengene宣布了其2025年的业绩,标志着与UCB为其AnTenGager TCE平台达成6000万美元的预付协议的一个关键里程碑,包括200万美元在短期里程石和潜在未来支付超过11亿美元. Antengene announced its 2025 results, marking a key milestone with a $60 million upfront deal with UCB for its AnTenGager TCE platform, including $20 million in near-term milestones and potential future payments exceeding $1.1 billion. 该协议涵盖了ATG-201,一种针对自身免疫疾病的CD19向治疗方法,而UCB将领导临床开发. The agreement covers ATG-201, a CD19-targeted therapy for autoimmune diseases, with UCB set to lead clinical development. Antengene计划在2026年对ATG-101进行关键的胃癌第三期试验,并推进针对固体瘤的其他项目,预计IND提交将于2027年. Antengene plans a pivotal Phase III trial for ATG-101 in gastric cancer in 2026 and advancing other programs targeting solid tumors, with IND submissions expected in 2027. 该公司的目标是通过有纪律的研发和全球合作伙伴关系,利用预付款,里程碑和版税来实现2026年的利. The company aims for profitability in 2026 through disciplined R&D and global partnerships, leveraging upfront payments, milestones, and royalties.